Amur Minerals (GB:CRTX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
CRISM Therapeutics Corporation, originally Amur Minerals, announced positive interim results following its AIM admission and Reverse Takeover, highlighting the development of ChemoSeed®, an innovative drug delivery technology for chemotherapy. The company is preparing for a Phase 2 clinical trial for high-grade glioma, with significant backing including an MHRA Innovation Passport and financial support from SPARK the Midlands. CRISM has also gained additional revenue through a service agreement with imphatec and is optimistic about the future application of ChemoSeed for various cancers.
For further insights into GB:CRTX stock, check out TipRanks’ Stock Analysis page.
